Xtandi Success Stories: PSA Drops and Real-World Results

Xtandi (enzalutamide) has built one of the strongest clinical track records of any oral prostate cancer drug, with large randomized trials showing survival benefits across nearly every stage of the disease. In men whose cancer had progressed after chemotherapy, the first major trial found that Xtandi extended median survival by about five months compared with placebo. Since then, success has been documented in progressively earlier settings, from metastatic castration-resistant disease all the way down to men whose only sign of cancer is a rising PSA after surgery or radiation. The evidence is deeper and more varied than a single headline number can capture, and the real stories of how Xtandi performs involve PSA responses, quality-of-life gains, pain control, and the practical challenges of staying on a drug long enough for it to work.

The Trial That Started It All

The AFFIRM trial enrolled men whose metastatic castration-resistant prostate cancer (mCRPC) had worsened after docetaxel chemotherapy. These patients had limited options, and their prognosis was poor. Xtandi extended median overall survival to about 18.4 months, compared with roughly 13.6 months for placebo, cutting the risk of death by about 37%. Beyond survival, more than half the men on Xtandi saw their PSA drop by at least 50%, compared with just 2% on placebo. Tumor shrinkage in soft tissue occurred in about 29% of patients, and quality-of-life improvements were reported at more than double the rate seen with placebo.¹

A subgroup analysis of AFFIRM showed these benefits held regardless of how high a man’s baseline PSA was. Whether PSA was in the lowest or highest quartile at the start of the trial, Xtandi consistently improved survival, radiographic progression-free survival, and time to PSA progression over placebo.² That mattered for patients and doctors alike, because a high starting PSA sometimes raises doubts about whether a treatment will work. In AFFIRM, it didn’t predict futility.

Even men already taking corticosteroids at baseline, often a sign of more advanced or symptomatic disease, benefited from Xtandi. Among corticosteroid users, median overall survival went from about 9.3 months on placebo to 12.3 months on Xtandi. Among non-users, the survival advantage was even larger, with the Xtandi group’s median survival not yet reached after 24 months of follow-up compared with about 15.8 months on placebo.³

Before Chemotherapy

The PREVAIL trial asked whether Xtandi could help men with mCRPC who had not yet received chemotherapy. The results were decisive. At the interim analysis, Xtandi cut the risk of radiographic progression or death by 68% and the risk of death by 23%. Median radiographic progression-free survival was about 20 months with Xtandi versus roughly 5.4 months with placebo.⁴

With five years of follow-up, the survival benefit held up. Median overall survival was 36 months in the Xtandi group versus 31 months in the placebo group, a 17% reduction in the risk of death. That gap persisted despite the fact that a majority of placebo patients eventually crossed over to receive Xtandi or other active treatments, which would tend to dilute the survival difference.⁵

Stopping Metastasis Before It Starts

Some men with castration-resistant prostate cancer have a rising PSA but no detectable spread on imaging. The PROSPER trial tested whether Xtandi could delay or prevent metastasis in these patients. Median metastasis-free survival was about 36.6 months in the Xtandi group versus roughly 14.7 months on placebo, a 71% reduction in the risk of metastasis or death.⁶ A later analysis confirmed that the drug also improved overall survival.⁷

For men in this situation, the prospect of keeping cancer from appearing on a bone scan for an extra two years was a tangible, meaningful gain. Non-metastatic CRPC can feel like a waiting game, and PROSPER showed Xtandi could push back the clock considerably.

Hormone-Sensitive Metastatic Disease

The ARCHES trial moved Xtandi into an even earlier setting: men with metastatic hormone-sensitive prostate cancer (mHSPC) who were still responding to standard testosterone-lowering therapy. Adding Xtandi to that backbone treatment reduced the risk of radiographic progression or death by about 61% compared with adding a placebo. The benefit was consistent across subgroups, including men with low-volume disease and those who had previously received chemotherapy.⁸

With longer follow-up, ARCHES showed a survival benefit too. Adding Xtandi cut the risk of death by 34%, and improvements extended across all secondary endpoints.⁹ A separate subgroup analysis confirmed that the progression-free survival benefit applied regardless of disease volume or risk category.¹⁰

Biochemical Recurrence After Surgery or Radiation

The EMBARK trial pushed the boundaries even further. It enrolled men with high-risk biochemical recurrence, meaning their PSA was rising after initial treatment but there was no sign of metastasis on conventional imaging. At five years, 87.3% of men receiving Xtandi plus leuprolide (a standard hormone therapy) were free of metastasis, compared with 71.4% on leuprolide alone. Xtandi as a single agent also outperformed leuprolide alone, with 80% metastasis-free survival at five years.¹¹

With longer follow-up, a clear overall survival benefit emerged. The eight-year overall survival rate was about 79% in the combination group versus roughly 70% with leuprolide alone, a 40% reduction in the risk of death.¹² Secondary endpoints reinforced the picture: at five years, men on the combination were far more likely to remain free of distant metastasis, castration resistance, symptomatic progression, and skeletal events.¹³

EMBARK represents one of the more striking “success stories” in recent prostate cancer research because these men had no visible metastases. Demonstrating a survival advantage in a population with relatively low disease burden is a high bar to clear.

What PSA Drops Actually Tell You

A falling PSA is the first tangible sign most patients see that their treatment is working, and the depth and speed of that drop carries real prognostic weight. In the AFFIRM trial population (post-chemotherapy mCRPC), about 88% of men on Xtandi had a confirmed PSA decline of at least 30% within three months, roughly 80% dropped by at least half, and about 39% achieved a deep response of 90% or more. Men who reached those deeper drops had longer survival, slower radiographic progression, and better quality of life than those whose PSA fell less.¹⁴

In hormone-sensitive metastatic disease, a secondary analysis of the ARCHES trial found that men who achieved an undetectable PSA on Xtandi plus hormone therapy had an 86% lower risk of radiographic progression and a 76% lower risk of death compared with those who did not reach that level.¹⁵ An undetectable PSA is the best early signal that the drug is doing its job, and while not every patient reaches it, those who do tend to have markedly better long-term outcomes.

Quality of Life and Pain Control

Survival numbers only tell part of the story. In the AFFIRM trial, Xtandi significantly delayed pain progression and reduced pain severity and interference scores compared with placebo. About 45% of patients who were evaluable for pain palliation reported improvement at 13 weeks, versus 7% on placebo. Quality-of-life deterioration was delayed from a median of about 3.7 months on placebo to 9 months on Xtandi, and overall improvement in health-related quality of life was reported in about 42% of Xtandi patients compared with 15% on placebo.¹⁶

Similar findings emerged from PREVAIL in the pre-chemotherapy setting. Quality-of-life deterioration was delayed to about 11.3 months with Xtandi versus 5.6 months on placebo, and about 40% of Xtandi patients reported clinically meaningful improvement in overall quality of life, compared with about 23% on placebo. Pain progression at 13 weeks was also less common with Xtandi.¹⁷

In a head-to-head trial against bicalutamide, an older anti-androgen, Xtandi also delayed quality-of-life deterioration more effectively. The risk of first deterioration in overall quality-of-life score was about 36% lower with Xtandi.¹⁸

How Results Look Outside Clinical Trials

Clinical trials enroll carefully selected populations, so it matters whether Xtandi performs comparably in everyday practice. A large real-world study of patients with mCRPC who had not received chemotherapy found an adjusted median overall survival of about 22.5 months for Xtandi, slightly higher than the 20.6 months observed with abiraterone. Patients starting on abiraterone had a roughly 10% higher risk of death compared with those starting on Xtandi.¹⁹

Another real-world study looked specifically at racial differences in Xtandi response. Black men and White men had similar rates of PSA decline at the 50% and 75% thresholds. Black men trended toward a somewhat higher rate of deep (90% or greater) PSA responses, though the difference was not statistically significant after adjusting for other factors. Median time to clinical progression was slightly longer for Black men (about 9.5 months versus 8.1 months), and in adjusted analyses, Black men had a lower risk of clinical progression.²⁰ This is reassuring because Black men are underrepresented in most prostate cancer clinical trials, and questions about whether trial results translate to this population are legitimate.

When Xtandi Stops Working

Almost all patients eventually develop resistance. The most well-studied mechanism involves a shortened form of the androgen receptor called AR-V7. This variant is missing the part of the receptor that Xtandi targets, so the drug cannot block it. Among men receiving Xtandi, those who tested positive for AR-V7 in their circulating tumor cells had a 0% PSA response rate, compared with 53% in AR-V7-negative patients. Median overall survival was about 5.5 months in the AR-V7-positive group versus not yet reached in the AR-V7-negative group.²¹ AR-V7 is considered a key driver of Xtandi resistance and currently cannot be targeted by available androgen-receptor-directed drugs.²²

Beyond AR-V7, researchers are exploring circulating tumor DNA (ctDNA) as a way to monitor treatment response and spot early failure. In one study of men with mCRPC, patients whose ctDNA was detectable at baseline had considerably worse outcomes than those whose ctDNA was undetectable (median overall survival of about 13.6 months versus 22.5 months). When ctDNA was still detectable after starting treatment, about 73% of those patients progressed within six months. Interestingly, ctDNA status appeared to be an even stronger predictor of outcomes than PSA response alone, particularly when the two gave conflicting signals.²³ This kind of monitoring is not yet standard practice, but it hints at a future where doctors can identify non-responders much earlier.

Drug Sequencing Matters

Many patients will eventually need both Xtandi and abiraterone acetate, another androgen-pathway drug. The order matters. A randomized crossover trial found that starting with abiraterone and switching to Xtandi at progression produced better results than the reverse sequence. Time to second PSA progression was about 19.3 months with abiraterone-first versus 15.2 months with Xtandi-first. When abiraterone was used second after Xtandi, only about 4% of patients had a PSA response, while about 36% responded to Xtandi given second after abiraterone.²⁴ A systematic review and meta-analysis of multiple studies confirmed the pattern: abiraterone followed by Xtandi produced significantly longer PSA progression-free survival than the reverse.²⁵

The sequencing landscape is shifting now that both drugs are being used earlier in the disease course. But for men reaching the castration-resistant stage who have not yet received either drug, the evidence still points toward keeping Xtandi in reserve as a second-line option rather than leading with it and leaving abiraterone with diminished activity later.

Combination With PARP Inhibitors

Recent trials have tested whether combining Xtandi with PARP inhibitors, a class of drugs that target DNA repair deficiencies, can improve outcomes. Preclinical work suggested the two drug classes could be synergistic, and several large phase III trials have now reported results. The clearest benefit has been seen in men whose tumors carry BRCA mutations, with progressively smaller benefit in tumors with other DNA repair defects and uncertain benefit in unselected populations.²⁶ Genomic testing of the tumor is becoming an important step in deciding whether one of these combinations makes sense for a given patient.

Side Effects Worth Knowing About

Xtandi works by blocking the androgen receptor, and because those receptors exist in the brain as well as in prostate tissue, the drug can cause central nervous system side effects that most prostate cancer treatments do not. Fatigue is the most common, reported in roughly a third of patients in controlled trials. Falls are also more frequent, occurring at about double the rate seen with standard care. A meta-analysis found that drugs in Xtandi’s class carried a more than twofold increase in the risk of cognitive problems and a twofold increase in the risk of seizure compared with placebo or standard-of-care arms.²⁷

Seizure risk gets the most attention, but it is rare in properly dosed patients. Animal studies showed that seizures were a dose-dependent effect, and in trials they generally occurred at higher-than-recommended doses or in combination with other medications that lower the seizure threshold.²⁸ A broader network meta-analysis confirmed the overall pattern: Xtandi showed significant increases across all assessed central nervous system side effects, while abiraterone had a somewhat narrower profile of risk.²⁹

The cognitive effects deserve more attention than they sometimes get. Androgen receptors in the brain play a role in attention and memory, and suppressing them can have real effects on daily functioning. Screening for mild cognitive impairment is achievable with simple questionnaires, and patients on Xtandi have regular clinic visits that create natural opportunities for early detection.³⁰

Older Patients and Dose Adjustments

Prostate cancer is predominantly a disease of older men, and a natural question is whether Xtandi works as well and is tolerated as safely in patients over 75. In the PREVAIL trial, elderly patients had a substantial survival benefit from Xtandi: median overall survival was about 32.4 months with the drug versus 25.1 months on placebo. Radiographic progression-free survival was even more dramatically improved. Side effects were broadly similar across age groups, with one notable exception: falls were much more common among older patients, particularly those receiving Xtandi. About 19% of elderly men on Xtandi had falls, compared with about 8% on placebo in the same age group.³¹

A separate study found no significant differences in survival endpoints between younger and older patients, and suggested Xtandi might be a particularly suitable option for older adults because of its higher PSA response rate in that group.³² For patients struggling with side effects, a systematic review found that reduced doses of Xtandi could lower the incidence of adverse events while maintaining effectiveness in selected patients.³³

One published case report illustrates this rather vividly. An elderly man inadvertently took only a quarter of the standard dose (40 mg instead of 160 mg) because he thought one capsule would be “enough.” His PSA still dropped dramatically, from the mid-teens down to a nadir of 0.05 ng/mL, and his response was deep and sustained for months.³⁴ A single case report doesn’t set clinical policy, but it does suggest that some patients may be getting more drug than they individually need, and that dose optimization deserves more research.

The Cost of Staying on Treatment

One of the underappreciated threats to Xtandi’s success in the real world is cost. Among Medicare Part D beneficiaries, median annual out-of-pocket costs for Xtandi were about $11,626, with wide variation depending on the specific plan and zip code.³⁵ In a study of adherence among Medicare beneficiaries prescribed oral prostate cancer therapies including Xtandi, the mean adherence rate was 75%, with the median monthly out-of-pocket cost around $706. Adherence dropped in patients over 85 and in those receiving low-income subsidies.³⁶

A formal cost-effectiveness analysis comparing Xtandi with abiraterone found Xtandi was slightly more expensive overall but generated enough additional quality-adjusted survival to be considered cost-effective at a conventional threshold.³⁷ But cost-effectiveness at a population level and affordability for an individual patient are different things. Anyone starting Xtandi should investigate insurance coverage, manufacturer assistance programs, and plan selection carefully. A drug cannot produce a success story if a patient cannot afford to keep taking it.